CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 179 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.

Quarter-by-quarter ownership
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$9,559,588
+6.9%
250,251
+0.9%
0.01%0.0%
Q2 2023$8,944,639
-36.7%
247,980
-33.0%
0.01%
-38.5%
Q1 2023$14,138,434
-34.6%
370,213
-2.5%
0.01%
-27.8%
Q4 2022$21,606,865
+75.9%
379,734
+22.2%
0.02%
+63.6%
Q3 2022$12,283,000
+5.7%
310,657
+17.6%
0.01%0.0%
Q2 2022$11,622,000
+2.0%
264,136
-7.6%
0.01%
+22.2%
Q1 2022$11,396,000
-8.5%
285,769
-7.7%
0.01%
+12.5%
Q4 2021$12,449,000
-2.9%
309,604
-1.8%
0.01%
-20.0%
Q3 2021$12,824,000
-10.3%
315,235
+0.1%
0.01%
-9.1%
Q2 2021$14,302,000
+2.8%
314,959
-5.6%
0.01%0.0%
Q1 2021$13,909,000
-4.3%
333,621
-1.9%
0.01%0.0%
Q4 2020$14,531,000
+76.9%
340,223
+8.9%
0.01%
+57.1%
Q3 2020$8,213,000
+1.0%
312,518
+3.0%
0.01%
-12.5%
Q2 2020$8,134,000
+50.3%
303,383
+0.9%
0.01%
+14.3%
Q1 2020$5,411,000
-43.4%
300,774
-44.2%
0.01%
-22.2%
Q4 2019$9,560,000
+107.7%
539,202
+81.7%
0.01%
+80.0%
Q3 2019$4,603,000
+64.0%
296,776
+81.7%
0.01%
+66.7%
Q2 2019$2,807,000
+9.9%
163,376
+3.0%
0.00%0.0%
Q1 2019$2,553,000
+8.6%
158,602
-1.3%
0.00%0.0%
Q4 2018$2,351,000
-28.2%
160,702
-10.9%
0.00%
-25.0%
Q3 2018$3,276,000
+2.8%
180,281
-4.6%
0.00%0.0%
Q2 2018$3,188,000
-16.7%
189,002
-3.3%
0.00%
-20.0%
Q1 2018$3,828,000
-7.7%
195,400
-4.6%
0.01%
-16.7%
Q4 2017$4,149,000
+20.8%
204,800
+3.6%
0.01%
+20.0%
Q3 2017$3,434,000
+37.7%
197,700
+1.6%
0.01%
+25.0%
Q2 2017$2,493,000
+1.1%
194,500
+2.2%
0.00%0.0%
Q1 2017$2,466,000
+25.8%
190,300
-4.1%
0.00%
+33.3%
Q4 2016$1,961,000
-18.2%
198,5000.0%0.00%
-25.0%
Q3 2016$2,398,000
+31.0%
198,500
-6.4%
0.00%
+33.3%
Q2 2016$1,830,000
-11.6%
212,100
-3.0%
0.00%0.0%
Q1 2016$2,071,000
-53.3%
218,700
-14.4%
0.00%
-57.1%
Q4 2015$4,430,000
+42.2%
255,600
+10.2%
0.01%
+40.0%
Q3 2015$3,116,000
-40.5%
232,0000.0%0.01%
-37.5%
Q2 2015$5,239,000
+56.0%
232,0000.0%0.01%
+60.0%
Q1 2015$3,359,0000.0%232,0000.0%0.01%0.0%
Q4 2014$3,359,000
+59.1%
232,0000.0%0.01%
+66.7%
Q3 2014$2,111,000
-7.9%
232,0000.0%0.00%0.0%
Q2 2014$2,292,000
+16.8%
232,000
-2.0%
0.00%0.0%
Q1 2014$1,962,000
+4165.2%
236,700
+5565.4%
0.00%
Q3 2013$46,000
+39.4%
4,1780.0%0.00%
Q2 2013$33,0004,1780.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2015
NameSharesValueWeighting ↓
TRAN CAPITAL MANAGEMENT, L.P. 1,084,118$61,686,2857.80%
SNYDER CAPITAL MANAGEMENT L P 3,983,814$226,679,0175.12%
First Light Asset Management, LLC 923,119$52,525,4714.88%
Redwood Investments, LLC 441,809$25,138,9323.37%
BERNZOTT CAPITAL ADVISORS 444,728$25,305,0233.27%
DOHENY ASSET MANAGEMENT /CA 46,050$2,6203.04%
Crawford Lake Capital Management, LLC 42,171$2,399,5302.75%
2Xideas AG 416,586$23,703,7432.51%
Granite Investment Partners, LLC 902,882$51,373,9862.14%
HighMark Wealth Management LLC 41,790$2,377,8511.79%
View complete list of HALOZYME THERAPEUTICS INC shareholders